(Adnkronos) - Nuove opzioni terapeutiche endocrine efficaci potrebbero aiutare la popolazione delle pazienti affetta da carcinoma mammario Er+/Her2 - avanzato o metastatico con mutazioni Esr1. È l’argomento di un corso che si è tenuto a Roma in cui esperti ed oncologi hanno discusso gli aspetti più rilevanti e critici nella definizione dell’algoritmo ottimale di trattamento, in Italia, di queste pazienti, sottolineando che le mutazioni di Esr1 sono un noto driver di resistenza alle terapie endocrine standard e finora difficili da trattare.
Category
🗞
NewsTranscript
00:00It was held in Rome an update course on the fight against carcinoma mammary ER positive HIR2 negative advanced metastatic with ESR1 mutations,
00:13which has seen the participation of numerous experts, oncologists and professors,
00:17who have been able to illustrate the need for new therapeutic and effective endocrine options
00:22that could help the population of patients affected by this pathology.
00:26Elastestrand is a new drug, a new antihormonal that belongs to the category of oral SERD,
00:33which stands for selective degradators of the estrogen receptor.
00:37In practice, it acts by inhibiting the function of the estrogen receptor,
00:42even when resistance mechanisms have been verified.
00:46The advantage for patients is that another step is avoided, that is, the time of chemotherapy is removed,
00:53because this endocrine therapy can now be administered in women who have escaped endocrine therapy in the first place.
00:59It is a bit that changes the global approach to patients with positive hormonal receptors,
01:04because the time of chemotherapy, which rightly scares our patients,
01:08moves away from months, many months, from the beginning of the metastasis, and it is certainly a step forward.
01:15During the course, the issue of tolerance and the effectiveness of this new oral therapy,
01:21which is useful to counteract the breast tumor.
01:24Oral therapy by patients is always a very well accepted therapy, because it is feasible at home.
01:30In the case of Elastestrand, we have an optimal toxicity profile, with not many side effects,
01:36and therefore it is a treatment suitable for patients with both a good performance status and a slightly lower performance status,
01:43because it does not require particular therapeutic presidia to tampon the 20 adverse toxicity.
01:50The aim of the ECM course, therefore, was to bring into discussion the most relevant and critical aspects
01:56in the definition of the optimal treatment algorithm in Italy for patients,
02:00emphasizing that the SR1 mutations are a well-known driver of resistance to standard endocrine therapies,
02:06and so far difficult to treat.
02:08Yes, SR1 is a mutation that arises precisely as a phenomenon of resistance under the inhibition of hormonal therapy.
02:16Therefore, patients who have this mutation have a lower response to traditional hormonal therapies,
02:23but instead a better response to Elastestrand.
02:26The research work carried out by an Italian company was of great importance,
02:30which contributed to the realization of the new Elastestrand therapy.
02:33Thanks to the commitment of the Minarini group, through a compassionate use program,
02:39we have given the opportunity to access this therapy in a few months to more than 100 patients,
02:46and others will have access to it in the coming weeks.
02:51We do not stop at this, but the commitment of the group is to continue to develop new molecules,
02:57both in the mammary carcinoma, but also in other solid types,
03:00in addition to the commitment that we also have in hematology for several months.